Provided by Tiger Trade Technology Pte. Ltd.

Pharvaris N.V.

36.37
-1.6300-4.29%
Post-market: 36.01-0.3600-0.99%19:30 EDT
Volume:580.26K
Turnover:21.30M
Market Cap:2.54B
PE:-12.15
High:38.20
Open:38.09
Low:36.08
Close:38.00
52wk High:43.25
52wk Low:20.65
Shares:69.86M
Float Shares:43.70M
Volume Ratio:0.47
T/O Rate:1.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9943
EPS(LYR):-3.4871
ROE:-70.46%
ROA:-42.32%
PB:7.35
PE(LYR):-10.43

Loading ...

Top Pharvaris Executive Cashes In on Major Insider Stock Sale

TIPRANKS
·
Yesterday

Pharvaris Chief Commercial Officer Wim Souverijns Sells USD 1.02 Million in Common Shares

Reuters
·
Sep 17

Morgan Stanley Reaffirms Their Buy Rating on Pharvaris (PHVS)

TIPRANKS
·
Sep 14

Pharvaris Director Robert Glassman Disposes of Common Shares Worth $300,396

Reuters
·
Sep 12

BioCryst Pharmaceuticals Faces Competitive Pressure in Hereditary Angioedema Treatment, RBC Says

MT Newswires Live
·
Sep 10

Analysts Conflicted on These Healthcare Names: Xeris Pharmaceuticals (XERS) and Pharvaris (PHVS)

TIPRANKS
·
Sep 10

Pharvaris Price Target Raised to $65.00/Share from $50.00 by Leerink Partners

Dow Jones
·
Sep 10

Sweden's Biovica Q1 Sales Rise on Pharma Services Growth

Reuters
·
Sep 09

Pharvaris President Lu Peng Disposes of USD 610,134 Common Shares

Reuters
·
Sep 09

Pharvaris (PHVS) Gets a Buy from Leerink Partners

TIPRANKS
·
Sep 09

Pharvaris price target raised to $65 from $52 at Jones

TIPRANKS
·
Sep 09

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Pharvaris (PHVS) and Zimmer Biomet Holdings (ZBH)

TIPRANKS
·
Sep 09

Pharvaris N.v. : RBC Raises Target Price to $62 from $52

THOMSON REUTERS
·
Sep 09

Pharvaris: Kbc Securities Raises Target Price to $49 from $39; Rating Buy

THOMSON REUTERS
·
Sep 09

Pharvaris price target raised to $75 from $50 at Oppenheimer

TIPRANKS
·
Sep 09

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Sep 09

Top Midday Gainers

MT Newswires Live
·
Sep 09

Pharvaris Shares Rise on Positive Results for Hereditary Angioedema Trial

Dow Jones
·
Sep 08

Wedbush Adjusts Pharvaris Price Target to $50 From $42, Maintains Outperform Rating

MT Newswires Live
·
Sep 08

Pharvaris rises 16.7%

TIPRANKS
·
Sep 08